Fairvalue-Calculator Fairvalue-Calculator
EN DE

Kissei Pharmaceutical Co (KSPHF) Fair Value & Analysis

Healthcare · US · Market cap $1.1B

Price$25.77
Fair Value$45.63
Upside+77.1%
Quality96/100
Evidence: Medium Range $34.22 – $57.03

Analysis

Kissei Pharmaceutical Co (KSPHF) currently trades at $25.77, while our model-based Fair Value estimate is $45.63 — implying the stock looks roughly 77.1% undervalued today. We read business quality at 96/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to …

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.